BioAge Labs Inc(BIOA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.39 | Insider Own | 31.58% | Shs Outstand | 45.8M | Perf Week | 7.41% |
| Market Cap | 0.27B | Forward P/E | - | EPS next Y | 8.27% | Insider Trans | -0.43% | Shs Float | 31.4M | Perf Month | -16.22% |
| Enterprise Value | -0.04B | PEG | - | EPS next Q | -0.63 | Inst Own | 61.47% | Short Float | 10.93% | Perf Quarter | -34.29% |
| Income | -0.09B | P/S | 26.32 | EPS this Y | -9.97% | Inst Trans | 11.81% | Short Ratio | 3.56 | Perf Half Y | -64.75% |
| Sales | 0.01B | P/B | 0.73 | EPS next 5Y | -3.84% | ROA | -26.27% | Short Interest | 3.43M | Perf YTD | -55.1% |
| Book/sh | 8.19 | P/C | 0.86 | EPS past 3/5Y | -24.49% - | ROE | -28.21% | 52W High | -77.11% ($25.95) | Perf Year | -22.66% |
| Cash/sh | 6.94 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.05% | 52W Low | 23.49% ($4.81) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.76% | Gross Margin | 97.58% | Volatility(W/M) | 9.4% 7.35% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -4.18 | Sales Y/Y TTM | 168.06% | Oper. Margin | -1026.28% | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.19 | EPS Q/Q | 3.24% | Profit Margin | -912.25% | RSI (14) | 44.28 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.19 | Sales Q/Q | 1.62% | SMA20 | 4.01% ($5.71) | Beta | 1.08 | Target Price | $32.56 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/5 | SMA50 | -20.48% ($7.47) | Rel Volume | 0.88 | Prev Close | $5.94 |
| Employees | 62 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 4.5% 63.65% | SMA200 | -62.65% ($15.9) | Avg Volume(3M) | 0.96M | Price | $5.94 |
| IPO | 2024/9/26 | Option/Short | Yes/Yes | Trades | 6287 | Volume | 845,276 | Change | - |
🧬 BioAge Labs (BIOA) is a clinical-stage biopharmaceutical company developing therapeutics for obesity and metabolic diseases, targeting the biology of human aging. Leveraging its aging data platform, the company identifies novel drug candidates and is advancing a pipeline that includes a lead obesity drug candidate, alongside collaborative research with global pharmaceutical companies.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded about as much as usual. That is 88% of its average volume.
BIOA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -10.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,632. Peers typically go for $211.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 61.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
XPH State Street SPDR S&P Pharmaceuticals ETF 0.01% 
PTH Invesco Dorsey Wright Healthcare Momentum ETF <0.01% 
PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF <0.01% 
DWAS Invesco Dorsey Wright SmallCap Momentum ETF <0.01% 
BBC Virtus Biotech Clinical Trials ETF <0.01% It ranks #46 of 83 in the industry
Based on market cap of $273M.
FAQ
What kind of company is BIOA?
BIOA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BIOA?
The market cap of BIOA is approximately $273M, ranking 3,763 within its sector.
What is the 52-week high and low for BIOA?
BIOA has recorded a 52-week high of $25.95 and a low of $4.81.
